Biotechnology firm Transgenomic, along with four global biopharmaceutical firms, is starting a new pilot clinical study with its Multiplexed ICE COLD-PCR (MX-ICP) liquid biopsy technology.

The firm developed Multiplexed ICE COLD-PCR for the ultra-sensitive detection of very-low-level genetic alterations, allowing it to be used as a tool for the identification of cancer biomarkers.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The technology reportedly works with virtually any type of patient sample, including tissue, blood, plasma, and urine.

The study has been designed to validate the accuracy and utility of using MX-ICP-based liquid biopsies, which analyse circulating tumour DNA in the blood to guide and monitor cancer clinical trials.

"One of the most important attributes of our MX-ICP technology is its potential for enabling the routine use of DNA analyses to guide and monitor cancer treatment."

Transgenomic president and CEO Paul Kinnon said: "One of the most important attributes of our MX-ICP technology is its potential for enabling the routine use of DNA analyses to guide and monitor cancer treatment, by replacing invasive and costly tissue biopsies with easily-accessible blood tests.

"A similar pilot study partnered with another major oncology company that we started earlier this year is going very well, fuelling our optimism that these studies will confirm the broad potential of MX-ICP liquid biopsies in diagnosing, monitoring, and managing cancer."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company will include variety of cancers and several different sequencing platforms in the study.

In the study, Transgenomi will have access to patient blood samples from the participating firms’ relevant clinical trials.

It will help the firm to generate supporting data to demonstrate the correlation between genomic analyses from FFPE tissue samples and those obtained using plasma samples enriched with Multiplexed ICE COLD-PCR.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact